Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 16Advanced Solid Tumors 6Advanced Solid Tumor 5Solid Tumors 4Solid Tumor 4Mesothelioma 3Unspecified Childhood Solid Tumor, Protocol Specific 1Resectable Colon Cancer 1Relapsed Solid Tumor 1Pseudomyxoma Peritonei 1Peritoneal Neoplasms 1Patients With Advanced or Metastatic Solid Tumors 1Mesothelioma, Malignant 1Malignant Solid Tumour 1MSI-H Colorectal Cancer 1Locally Advanced and Metastatic Solid Tumors 1HER2-positive 1DMMR Colorectal Cancer 1Childhood Central Nervous System Choriocarcinoma 1Advanced Solid Tumour 1Advanced Solid Tumor Cancer 1

Interventions

sintilimab 1Trastuzumab 1S 1 (combination) 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive × Oxaliplatin × Other solid neoplasm × Clear all
NCT05218148 2022-04-06

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

ChineseAMS

Phase 2 Unknown
44 enrolled
GastrointestinalOther solid neoplasm

HER2-positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡